LB Pharmaceuticals Inc Common Stock
NASDAQ: LBRX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Heather D. Turner
- Employees
- 16
- Headquarters
- New York, United States
- IPO year
- 2025
- Market cap
- $874.1M
- Website
- https://lbpharma.us
Loading LBRX…
Loading profile data…Frequently asked questions about LBRX
What does LB Pharmaceuticals Inc Common Stock (LBRX) do?
This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, their primary investigational drug, which is a methylated variant of amisulpride.
Where does LBRX trade?
LB Pharmaceuticals Inc Common Stock (LBRX) trades on the NASDAQ Global Select.
What sector is LBRX in?
LB Pharmaceuticals Inc Common Stock (LBRX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of LB Pharmaceuticals Inc Common Stock?
Heather D. Turner is the chief executive officer of LB Pharmaceuticals Inc Common Stock (LBRX).
Where is LB Pharmaceuticals Inc Common Stock headquartered?
LB Pharmaceuticals Inc Common Stock is headquartered in United States.
Does LBRX pay a dividend?
LB Pharmaceuticals Inc Common Stock (LBRX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did LBRX go public?
LB Pharmaceuticals Inc Common Stock (LBRX) completed its initial public offering in 2025.